Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Research & Development (2019 - 2025)

Harmony Biosciences Holdings' Research & Development history spans 7 years, with the latest figure at $85.1 million for Q4 2025.

  • For Q4 2025, Research & Development rose 145.46% year-over-year to $85.1 million; the TTM value through Dec 2025 reached $189.6 million, up 30.01%, while the annual FY2025 figure was $189.6 million, 30.01% up from the prior year.
  • Research & Development for Q4 2025 was $85.1 million at Harmony Biosciences Holdings, up from $55.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $85.1 million in Q4 2025 and bottomed at $4.7 million in Q1 2021.
  • The 5-year median for Research & Development is $16.2 million (2023), against an average of $25.6 million.
  • The largest annual shift saw Research & Development soared 324.76% in 2024 before it crashed 76.41% in 2025.
  • A 5-year view of Research & Development shows it stood at $7.5 million in 2021, then soared by 35.44% to $10.1 million in 2022, then skyrocketed by 200.3% to $30.3 million in 2023, then rose by 14.39% to $34.7 million in 2024, then soared by 145.46% to $85.1 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Research & Development are $85.1 million (Q4 2025), $55.0 million (Q3 2025), and $15.0 million (Q2 2025).